Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Changes in Carrying Amount of Goodwill

The changes in the carrying amount of goodwill for the years ended December 31, 2013 and 2012 are as follows:

(In thousands)	Generics Segment			Specialty Segment			Total
Balance at December 31, 2011:
Goodwill	$	3,196,428		$	706,507		$	3,902,935
Accumulated impairment losses	—			(385,000		)	(385,000		)
	3,196,428			321,507			3,517,935
Foreign currency translation	(2,280		)	—			(2,280		)
	3,194,148			321,507			3,515,655
Balance at December 31, 2012:
Goodwill	3,194,148			706,507			3,900,655
Accumulated impairment losses	—			(385,000		)	(385,000		)
	3,194,148			321,507			3,515,655
Goodwill acquired (1)	903,998			—			903,998
Transfers (2)	(27,602		)	27,602			—
Foreign currency translation	(131,529		)	—			(131,529		)
	3,939,015			349,109			4,288,124
Balance at December 31, 2013:
Goodwill	3,939,015			734,109			4,673,124
Accumulated impairment losses	—			(385,000		)	(385,000		)
	$	3,939,015		$	349,109		$	4,288,124

____________

⁽¹⁾  See Note 3.

⁽²⁾  As a result of the January 1, 2013 reorganization of certain components between the Generics and Specialty segments, the Company was required to reassign a portion of the carrying amount of goodwill to the Specialty segment.

Components of Intangible Assets

Intangible assets consist of the following components at December 31, 2013 and 2012:

(In thousands)	Weighted Average Life (Years)	Original Cost		Accumulated Amortization		Net Book Value
December 31, 2013
Amortized intangible assets:
Patents and technologies	20	$	116,631	$	93,761	$	22,870
Product rights and licenses	10	3,559,505		2,018,111		1,541,394
Other (1)	8	173,974		59,395		114,579
		3,850,110		2,171,267		1,678,843
In-process research and development		839,045		—		839,045
		$	4,689,155	$	2,171,267	$	2,517,888
December 31, 2012
Amortized intangible assets:
Patents and technologies	20	$	116,631	$	88,288	$	28,343
Product rights and licenses	10	3,459,980		1,749,424		1,710,556
Other (1)	8	111,033		51,384		59,649
		3,687,644		1,889,096		1,798,548
In-process research and development		425,909		—		425,909
		$	4,113,553	$	1,889,096	$	2,224,457

____________

⁽¹⁾  Other intangibles consist principally of customer lists and contracts.

Product Rights and Licenses by Therapeutic Category

Product rights and licenses are primarily comprised of the products marketed at the time of acquisition. These product rights and licenses relate to numerous individual products, the net book value of which, by therapeutic category, is as follows:

(In thousands)	December 31, 2013		December 31, 2012
Allergy	$	95,911	$	111,386
Anti-infectives	194,220		145,109
Antineoplastic	147,414		51,251
Cardiovascular	235,777		309,062
Central Nervous System	211,205		273,102
Dermatological	79,576		93,644
Endocrine and Metabolic	72,400		80,702
Gastrointestinal	95,184		121,823
Respiratory System	147,448		218,658
Other (1)	262,259		305,819
	$	1,541,394	$	1,710,556

____________

⁽¹⁾  Other consists of numerous therapeutic classes, none of which individually exceeds 5% of total product rights and licenses.